217 related articles for article (PubMed ID: 35841997)
1. Anti-angiogenic nano-delivery system promotes tumor vascular normalizing and micro-environment reprogramming in solid tumor.
Shen R; Peng L; Zhou W; Wang D; Jiang Q; Ji J; Hu F; Yuan H
J Control Release; 2022 Sep; 349():550-564. PubMed ID: 35841997
[TBL] [Abstract][Full Text] [Related]
2. "Targeted plus controlled" - Composite nano delivery system opens the tumor vascular and microenvironment normalization window for anti-tumor therapy.
Shen R; Jiang Q; Li P; Wang D; Yu C; Meng T; Hu F; Yuan H
Int J Pharm; 2023 Nov; 647():123512. PubMed ID: 37839496
[TBL] [Abstract][Full Text] [Related]
3. Normalization of the tumor microvasculature based on targeting and modulation of the tumor microenvironment.
Li Z; Ning F; Wang C; Yu H; Ma Q; Sun Y
Nanoscale; 2021 Oct; 13(41):17254-17271. PubMed ID: 34651623
[TBL] [Abstract][Full Text] [Related]
4. Normalization of the vasculature for treatment of cancer and other diseases.
Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
[TBL] [Abstract][Full Text] [Related]
5. Reinforcing vascular normalization therapy with a bi-directional nano-system to achieve therapeutic-friendly tumor microenvironment.
Deng Y; Jiang Z; Jin Y; Qiao J; Yang S; Xiong H; Yao J
J Control Release; 2021 Dec; 340():87-101. PubMed ID: 34662587
[TBL] [Abstract][Full Text] [Related]
6. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
7. Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization.
Nikmaneshi MR; Jain RK; Munn LL
PLoS Comput Biol; 2023 Jun; 19(6):e1011131. PubMed ID: 37289729
[TBL] [Abstract][Full Text] [Related]
8. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.
Li S; Zhang Q; Hong Y
Technol Cancer Res Treat; 2020; 19():1533033820980116. PubMed ID: 33287656
[TBL] [Abstract][Full Text] [Related]
9. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
Fukumura D; Jain RK
Microvasc Res; 2007; 74(2-3):72-84. PubMed ID: 17560615
[TBL] [Abstract][Full Text] [Related]
10. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
11. Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential.
Ruan L; Zhang S; Chen X; Liang W; Xie Q
Pathol Res Pract; 2022 Aug; 236():153956. PubMed ID: 35700578
[TBL] [Abstract][Full Text] [Related]
12. Image-based modeling of vascular organization to evaluate anti-angiogenic therapy.
Ascheid D; Baumann M; Funke C; Volz J; Pinnecker J; Friedrich M; Höhn M; Nandigama R; Ergün S; Nieswandt B; Heinze KG; Henke E
Biol Direct; 2023 Mar; 18(1):10. PubMed ID: 36922848
[TBL] [Abstract][Full Text] [Related]
13. Nano-targeting vascular remodeling in cancer: Recent developments and future directions.
Giordo R; Wehbe Z; Paliogiannis P; Eid AH; Mangoni AA; Pintus G
Semin Cancer Biol; 2022 Nov; 86(Pt 2):784-804. PubMed ID: 35257860
[TBL] [Abstract][Full Text] [Related]
14. Tumor Vasculatures: A New Target for Cancer Immunotherapy.
Liu Z; Wang Y; Huang Y; Kim BYS; Shan H; Wu D; Jiang W
Trends Pharmacol Sci; 2019 Sep; 40(9):613-623. PubMed ID: 31331639
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor vascularization: promising strategies for vascular normalization.
Zheng R; Li F; Li F; Gong A
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2489-2505. PubMed ID: 34148156
[TBL] [Abstract][Full Text] [Related]
16. Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity.
Tzeng HT; Huang YJ
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901858
[TBL] [Abstract][Full Text] [Related]
17. Abnormal tumor vasculatures and bone marrow-derived pro-angiogenic cells in cancer.
Mizukami Y; Sasajima J; Ashida T; Kohgo Y
Int J Hematol; 2012 Feb; 95(2):125-30. PubMed ID: 22311464
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenesis: Opening a new window for immunotherapy.
Guo F; Cui J
Life Sci; 2020 Oct; 258():118163. PubMed ID: 32738363
[TBL] [Abstract][Full Text] [Related]
19. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.
Qian C; Liu C; Liu W; Zhou R; Zhao L
Front Immunol; 2023; 14():1291530. PubMed ID: 38193080
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
